ILLUMINA INC (ILMN)
US4523271090 - Common Stock
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of...
Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024
/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday,...
Charles Dadswell to step down as General Counsel, Illumina initiates search for successor
/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that after 11 years of service,...
EU’s Illumina Defeat Sparks Dutch Call for More Deal Powers
The Dutch competition watchdog is seeking beefed-up powers to probe more small deals that risk crushing competition in fledgling tech markets after the European Union’s attempts to vet them was shot down by the bloc’s top court.
Bull of the Day: Illumina (ILMN)
Big jump after earnings led by a pullback, could be an opportunity here.
European Court of Justice rules in favor of Illumina in jurisdictional appeal
/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's)...
Illumina-Grail Deal Was Wrongly Probed by EU, Top Court Rules
Illumina Inc.’s abandoned $7 billion bid for cancer-detection provider Grail Inc. should never have been probed by the European Union, according to a top court ruling that strikes at the heart of the EU’s attempt to vet more global deals.
Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
/PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed...
The Zacks Analyst Blog Highlights DaVita and Illumina
DaVita and Illumina are included in this Analyst Blog.
ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
Nasdaq 100 Movers: SMCI, GILD
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration...
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Nasdaq 100 Movers: AMAT, ILMN